Search research articles
Contact Us
Filters
Showing results (431-440 of 442) with videos related to
Page
of 45
Sort By:
Translational Psychiatry
|
August 29, 2013
Peripheral and central nervous system inhibition of 11β-hydroxysteroid dehydrogenase type 1 in man by the novel inhibitor ABT-384
D A Katz, W Liu, C Locke, et al.
Physical Review Letters
|
September 28, 2004
Neutron-detected tomography of impurity-seeded superfluid helium
M E Hayden, G Archibald, P D Barnes, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
September 17, 2009
In vitro and in vivo evidence for a lack of interaction with dopamine D2 receptors by the metabotropic glutamate 2/3 receptor agonists 1S,2S,5R,6S-2-aminobicyclo[3.1.0]hexane-2,6-bicaroxylate monohydrate (LY354740) and (-)-2-oxa-4-aminobicyclo[3.1.0] Hexane-4,6-dicarboxylic acid (LY379268)
Matthew J Fell, Kenneth W Perry, Julie F Falcone, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
March 17, 2019
Imaging the Enzyme 11β-Hydroxysteroid Dehydrogenase Type 1 with PET: Evaluation of the Novel Radiotracer <sup>11</sup>C-AS2471907 in Human Brain
Jean-Dominique Gallezot, Nabeel Nabulsi, Shannan Henry, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
January 6, 2007
Pharmacological and pharmacokinetic properties of a structurally novel, potent, and selective metabotropic glutamate 2/3 receptor agonist: in vitro characterization of agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]-hexane-4,6-dicarboxylic acid (LY404039)
Linda M Rorick-Kehn, Bryan G Johnson, Jennifer L Burkey, et al.
Leukemia
|
April 5, 2017
Benefit of continuous treatment for responders with newly diagnosed multiple myeloma in the randomized FIRST trial
N J Bahlis, A Corso, L-O Mugge, et al.
Journal of Psychopharmacology (Oxford, England)
|
October 16, 2025
A novel psychedelic 5-HT<sub>2A</sub> receptor agonist GM-2505: The pharmacokinetic, safety, and pharmacodynamic profile from a randomized trial healthy volunteer
Gerard J Marek, Soma Makai-Bölöni, Daniel Umbricht, et al.
Physical Review Letters
|
January 7, 2003
Measurements of ultracold-neutron lifetimes in solid deuterium
C L Morris, J M Anaya, T J Bowles, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
October 16, 2010
N-(4-((2-(trifluoromethyl)-3-hydroxy-4-(isobutyryl)phenoxy)methyl)benzyl)-1-methyl-1H-imidazole-4-carboxamide (THIIC), a novel metabotropic glutamate 2 potentiator with potential anxiolytic/antidepressant properties: in vivo profiling suggests a link between behavioral and central nervous system neurochemical changes
Matthew J Fell, Jeffrey M Witkin, Julie F Falcone, et al.
Physical Review Letters
|
March 21, 2008
First observation of the Greisen-Zatsepin-Kuzmin suppression
R U Abbasi, T Abu-Zayyad, M Allen, et al.
Page
of 45
Search research articles
Search
Showing results (431-440 of 442) with videos related to
Sort By:
Page
of 45
Translational Psychiatry
|
August 29, 2013
Peripheral and central nervous system inhibition of 11β-hydroxysteroid dehydrogenase type 1 in man by the novel inhibitor ABT-384
D A Katz, W Liu, C Locke, et al.
Physical Review Letters
|
September 28, 2004
Neutron-detected tomography of impurity-seeded superfluid helium
M E Hayden, G Archibald, P D Barnes, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
September 17, 2009
In vitro and in vivo evidence for a lack of interaction with dopamine D2 receptors by the metabotropic glutamate 2/3 receptor agonists 1S,2S,5R,6S-2-aminobicyclo[3.1.0]hexane-2,6-bicaroxylate monohydrate (LY354740) and (-)-2-oxa-4-aminobicyclo[3.1.0] Hexane-4,6-dicarboxylic acid (LY379268)
Matthew J Fell, Kenneth W Perry, Julie F Falcone, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
March 17, 2019
Imaging the Enzyme 11β-Hydroxysteroid Dehydrogenase Type 1 with PET: Evaluation of the Novel Radiotracer <sup>11</sup>C-AS2471907 in Human Brain
Jean-Dominique Gallezot, Nabeel Nabulsi, Shannan Henry, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
January 6, 2007
Pharmacological and pharmacokinetic properties of a structurally novel, potent, and selective metabotropic glutamate 2/3 receptor agonist: in vitro characterization of agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]-hexane-4,6-dicarboxylic acid (LY404039)
Linda M Rorick-Kehn, Bryan G Johnson, Jennifer L Burkey, et al.
Leukemia
|
April 5, 2017
Benefit of continuous treatment for responders with newly diagnosed multiple myeloma in the randomized FIRST trial
N J Bahlis, A Corso, L-O Mugge, et al.
Journal of Psychopharmacology (Oxford, England)
|
October 16, 2025
A novel psychedelic 5-HT<sub>2A</sub> receptor agonist GM-2505: The pharmacokinetic, safety, and pharmacodynamic profile from a randomized trial healthy volunteer
Gerard J Marek, Soma Makai-Bölöni, Daniel Umbricht, et al.
Physical Review Letters
|
January 7, 2003
Measurements of ultracold-neutron lifetimes in solid deuterium
C L Morris, J M Anaya, T J Bowles, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
October 16, 2010
N-(4-((2-(trifluoromethyl)-3-hydroxy-4-(isobutyryl)phenoxy)methyl)benzyl)-1-methyl-1H-imidazole-4-carboxamide (THIIC), a novel metabotropic glutamate 2 potentiator with potential anxiolytic/antidepressant properties: in vivo profiling suggests a link between behavioral and central nervous system neurochemical changes
Matthew J Fell, Jeffrey M Witkin, Julie F Falcone, et al.
Physical Review Letters
|
March 21, 2008
First observation of the Greisen-Zatsepin-Kuzmin suppression
R U Abbasi, T Abu-Zayyad, M Allen, et al.
Page
of 45